Another study using beclin-1 was performed using an MJD/SCA3 transgenic mouse model with a severe motor phenotype [43] and aimed to evaluate the efficiency of the gene-based delivery of beclin-1 to induce autophagy and revert the disease phenotype. This evidence concerns the gene ATXN3 and Spinocerebellar ataxia type 3.